Musculoskeletal Ultrasound Assessment Changes Management Decisions in Rheumatoid Arthritis Patients With Moderate Disease Activity
International Journal of Rheumatic Diseases · 2025
DOI: 10.1111/1756-185x.70415 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2025. Verfasst von Helena Crawshaw und 8 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Department, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Clinical Decision-Making, Joints. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Background
Musculoskeletal ultrasound (MSUS) provides valuable information about disease activity and anatomical damage in rheumatoid arthritis (RA); therefore, in combination with clinical assessment, it may be a useful tool in clinical decision‐making with treatment.
Objectives
(1) To evaluate the impact of MSUS assessment on treatment decisions in patients with moderately active RA receiving conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs). (2) To determine the level of concordance between MSUS assessment and DAS28 in these patients.
Methods
RA patients with a DAS‐28 ranging from 3.22–5.1, inadequate response to csDMARDs, and indication for escalating treatment were enrolled. All patients underwent an ultrasound (US) examination (B and PD modes) of the bilateral 5‐joint count (5USJC), the symptomatic joints of the DAS‐28 score (28USJC), and of a comprehensive 78‐joint count (78USJC). A Likert scale (pre‐ and post‐MSUS) was used to assess patients' and clinicians' desires to escalate treatment. The outcome of the treatment decision based on US assessment was reviewed at 24 months' follow‐up.
Results
Among the 27 patients included, the mean (SD) DAS‐28 score was 4.4 (0.7). Following US assessment, there was a change in the decision to escalate treatment in 18 patients (66.7%), and at a median follow‐up of 24 months, only in 5 of the 18 patients had the treatment had been escalated. Treatment escalation was associated with a higher US score across all assessments (5USJC, 28USJC, 78USJC) ( p < 0.05). The 78USJC was the most reliably aligned with the treatment decision ( p = 0.009). A comparison of the US and clinical assessment revealed poor concordance between all variables of the DAS‐28 and US scores, except for the swollen joint count.
Conclusion
The addition of MSUS assessment to the DAS‐28 score affected management decisions in 66.7% of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rheumatology Department, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.
- Preventive Medicine, Vithas Group Hospitals, Madrid, Spain.
ORCID-Profile: Carlos Acebes
Zitieren
APA
Crawshaw, H., Rubio-Cirilo, L., Johnson, H., Jamal, S., Hickey, S., Gunn, J., Ali, I., Coombes, G., & Acebes, C. (2025). Musculoskeletal Ultrasound Assessment Changes Management Decisions in Rheumatoid Arthritis Patients With Moderate Disease Activity. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70415
Vancouver
Crawshaw H, Rubio-Cirilo L, Johnson H, Jamal S, Hickey S, Gunn J, et al. Musculoskeletal Ultrasound Assessment Changes Management Decisions in Rheumatoid Arthritis Patients With Moderate Disease Activity. International Journal of Rheumatic Diseases. 2025. doi:10.1111/1756-185x.70415
BibTeX
@article{Crawshaw2025,
author = {Crawshaw, Helena and Rubio-Cirilo, Laura and Johnson, Hilary and Jamal, Safwan and Hickey, Sarah and Gunn, Jessica and Ali, Iman and Coombes, Gill and Acebes, Carlos},
title = {Musculoskeletal Ultrasound Assessment Changes Management Decisions in Rheumatoid Arthritis Patients With Moderate Disease Activity},
journal = {International Journal of Rheumatic Diseases},
year = {2025},
doi = {10.1111/1756-185x.70415}
}
EUVIMED